我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • Genamics 期刊搜索
  • 宇宙IF
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

A Multicenter Study on Neuropathic Pain in China: Characteristics and the Efficacy of Pregabalin

He L, Yan ZW, Shen QY, Wang YD and Peng Y

Background: This clinical study aims to analyse the characteristics of neuropathic pain patients across country nationwide and evaluate the efficacy and tolerability of pregabalin for the treatment of neuropathic pain. The GABA analogue, pregabalin, is being studied to try to establish standardized management of neuropathic pain as it is commonly used in postherpetic neuralgia in China.
Methods: Patients with neuropathic pain from 17 hospitals were included for four weeks. The demographics and baseline characteristics of patients were analyzed. The primary outcome was the difference in the pain intensity scores in the numerical rating scale from baseline to follow-up visits. Secondary outcomes included the differing visual analogue scale (VAS) of the short-form McGill Pain Questionnaire, sleep quality, anxiety and depression scores, and side effects during four weeks of follow-up.
Results: As 355 patients completed the 4-week follow up, various types of neuropathic pain intensity scores significantly decreased at the first week of treatment and improved through the course of the study. Meanwhile; the difference in the percentage change in patient global impression of change scores, mean sleep interference scores, anxiety and depression scores are all significantly higher after 4-week treatment. Most of the side effects went away during treatment as patients adjust to the medicine.
Conclusions: The data demonstrated that pregabalin was effective and well tolerated in Chinese patients with neuropathic pains. This study also analyzed the distribution features of neuropathic pain in a general population and established standardized management of neuropathic pain in China.